<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481884</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0827</org_study_id>
    <nct_id>NCT00481884</nct_id>
  </id_info>
  <brief_title>Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients</brief_title>
  <official_title>Phase III Trial to Compare RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine if RadiaPlexRx Hydrogel can reduce the development of grade 2 or higher
      radiation dermatitis in breast cancer from adjuvant radiation when compared to a
      petroleum-based gel (Aquaphor) commonly used as best supportive care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Gels:

      RadiaPlexRx (requires a prescription) and Aquaphor (over-the-counter) are both gels that are
      designed to treat irradiated (received radiation) breast skin.

      These 2 gels contain different ingredients that may make one gel better than the other to
      treat irradiated breast skin. RadiaPlexRx contains hyaluronic acid (an ingredient found
      naturally in skin), aloe vera, and other ingredients that help the skin heal. Aquaphor is
      made of mostly petroleum that helps protect the skin.

      Application of Study Gels:

      If you decide to participate in this study, the following steps will be taken:

        -  You will be given detailed instructions on how to apply both of the gels. You should not
           apply other gels or lotions on the areas of skin where you will be instructed to apply
           the study gels, unless you are instructed to do so by the treating doctor.

        -  You will receive a supply of both gels (in tubes) with enough to last for the length of
           your treatment. You will know which gel is which, but each gel will be labeled with
           &quot;outer&quot; or &quot;inner&quot; so that you will know which gel to use on which side. You should not
           tell your treating doctor which side of the breast skin is being treated with which gel
           so that a fair comparison of the gels can be made.

        -  You will apply 1 gel to the outer side of the irradiated breast skin and the other gel
           to the inner side of the irradiated breast skin.

        -  If you experience any kind of allergic reaction (such as a rash) to the study gels, you
           should notify the study doctor or study staff immediately.

      Schedule for Study Gels:

      You will need to follow the schedule for applying the gels as follows:

        -  You will need to apply both gels starting 1 day before the start of radiation
           treatments.

        -  You will then need to apply both gels for 6 weeks during radiation treatment.

        -  During the study period (1 day before the start of radiation treatment, during 6 weeks
           of radiation treatment), you will need to apply both gels 3 times (in the morning,
           afternoon, and evening just before going to sleep) each day at home.

        -  During the days that you receive radiation treatment, you will be asked to apply the
           gels immediately after you receive your radiation treatment. This will count as 1 of the
           3 daily gel applications.

      Clinic Visits:

      You will have the following tests done during your clinic visits:

        -  Three (3) sets of photos of your breast skin will be taken (before radiation starts and
           during Weeks 3 and 6 of radiation therapy treatment).

        -  During Weeks 1 through 6, you will go to the clinic to have your skin checked by your
           treating physician to learn the effects of each gel on your symptoms. .

        -  You will need to return any empty tubes of study gel so that new tubes can be given if
           you will need more.

      Length of Study:

      If the treating doctor sees that the irradiated breast skin reacts poorly (does not improve
      or gets worse) or you experience any intolerable side effects, you will be taken off this
      study. Otherwise, the total time on this study is about 6 weeks.

      End-of-Study:

      -During your last week of radiation therapy treatment you will be asked to fill out a
      questionnaire about how you felt about each gel.

      This is an investigational study. RadiaPlexRx and Aquaphor are both FDA approved and
      commercially available. Up to 92 patients will take part in this study. All will be enrolled
      at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients using RadiaPlexRx Hydrogel that developed grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>RadiaPlexRx Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquaphor Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RadiaPlexRx Gel</intervention_name>
    <description>RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.</description>
    <arm_group_label>RadiaPlexRx Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aquaphor Gel</intervention_name>
    <description>Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.</description>
    <arm_group_label>Aquaphor Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted)

          2. Patient has breast conserving surgery (lumpectomy) for breast cancer with negative
             surgical margin

          3. Stage Tis,0-3 N0-2 M0

          4. Patient will receive irradiation of whole breast. An additional field to treat the
             supraclavicular / axillary apex lymphatics is allowed, but a separate field to treat
             the internal mammary chain nodes is not allowed

          5. The breast will receive radiation dose greater than or equal to 50 Gy, with or without
             a boost field to give additional dose to the tumor bed

          6. Patient wears bras with cup size larger than A

          7. Patient signs informed consent

        Exclusion Criteria:

          1. Breast cancer treatment with mastectomy

          2. Stage T4 breast cancer

          3. Patient will require the use of tissue-equivalent bolus during radiation treatment or
             double treatment of junctions of radiation treatment fields

          4. Patient will require treatment to the internal mammary chain lymph node bed using a
             separate radiation electron field

          5. Patient is planned for partial-breast irradiation or Mammo-site treatment.

          6. Patient has unhealed wound or rash in the radiation field

          7. Patient has allergy to RadiaPlexRx or aloe vera

          8. Patient has systemic lupus erythematosus or scleroderma that increases the risk of
             radiation dermatitis development

          9. Patient will receive concurrent chemotherapy with radiation. (Patient is allowed to
             take concurrent hormonal therapy or HerceptinÂ® [Trastuzumab])

         10. Planned accelerated fractionation.

         11. Planned radiation therapy to the bilateral breasts

         12. Planned breast irradiation in the prone position
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Buchholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Radiation Dermatitis</keyword>
  <keyword>RadiaPlexRx Gel</keyword>
  <keyword>Aquaphor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

